ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

A de-escalation of tyrosine-kinase inhibitor dose was safe in the majority of patients with chronic myeloid leukemia with stable major molecular response.

Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population.

This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.

Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients.

Chromosomal abnormalities such as a variant t(9;22) translocation do not appear to have significant prognostic impact on children with chronic myeloid leukemia.

Insurance status at the time of chronic myeloid leukemia diagnosis appears to have an influence on survival outcomes, with the uninsured and those on Medicaid having worse overall survival.

This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia.

Pages

Subscribe to Chronic Myeloid Leukemia on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.